Strong Full-Year Revenue Growth
Fiscal year 2025 revenue reached RMB 3.98 billion, up 43.5% year-over-year, reflecting robust top-line expansion across the business.
Quarterly Revenue Surge
Fourth quarter revenue more than doubled year-over-year to RMB 1.41 billion, a 105.5% increase, indicating strong acceleration into the year-end.
Insurance Segment Outperformance
Full-year insurance revenue was approximately RMB 3.58 billion, up 51.3% year-over-year; the insurance-related income in Q4 surged 125% year-over-year to RMB 1.31 billion. Reported operating margin for the segment was roughly 18%.
Profitability and Quarterly Net Income Growth
Company reported GAAP profitability for 16 consecutive quarters. Fourth-quarter net profit attributable to ordinary shareholders was RMB 153 million, up 62.7% year-over-year. Full-year net profit attributable was reported as RMB 570 million.
Capital Return and Share Repurchase
Board approved a cash dividend of CNY 0.03 per ADS totaling approximately $10.8 million and the company has repurchased 60.7 million ADS for about $118 million, supporting shareholder returns and confidence in the balance sheet.
AI and Technology Advancements
Company filed 72 LLM-related patent applications and integrated LLM/AI across core workflows (acquisition, customer service, QC, R&D). AI-driven features delivered measurable results: an AI mini-program drove a 33% sequential increase in premium and AI medical experts produced strong sequential gains (large QoQ increases reported). The company plans to embed AI company-wide and pursue industry collaboration platforms.
Healthcare Platform and Product Innovation
Medical platform served 3.68 million patients and the digital team enrolled over 4,000 patients in the year. The healthcare business enrolled 224 pharmaceutical companies and launched a record number of programs (131 new programs this quarter). Proprietary patient-matching technology received a national invention patent and reduced manual screening workflows to approximately 2 minutes.
Digital Clinical Trial and Medical Services Growth
Digital clinical trial-related revenue and medical performance services showed notable growth, with references to ~30% growth in digital clinical trial revenue in the quarter and medical performance services at approximately RMB 260 million for the year.
ESG Improvements and Recognition
Company partnered with 19 organizations to launch over 15,500 products with global recognition for carbon reduction efforts, resulting in an upgraded ESG rating to A+.